Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference Product Clear all
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

NCT00666328
View directory record Official record
Conditions
Hypertension, Hemorrhage
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.

NCT01173627
View directory record Official record
Conditions
Pain
Interventions
Test fentanyl citrate 400 mcg troche, Actiq 400 mcg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Not applicable Interventional

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

NCT02064829
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions
Nab-paclitaxel, IG-001
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
30 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Fayetteville, Arkansas • Chattanooga, Tennessee • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

NCT07220551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UCB0022
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood

NCT04054661
View directory record Official record
Conditions
G6PD Deficiency
Interventions
SD Biosensor STANDARD G6PD Test, Pointe Scientific Test Kit, HemoCue System
Diagnostic Test
Lead sponsor
PATH
Other
Eligibility
18 Years to 65 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Quality of Life Parameters Following Use of Emergen-C

NCT06654089
View directory record Official record
Conditions
Dietary Supplements
Interventions
Emergen-C Core Super Orange Powder, Placebo
Dietary Supplement
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 64 Years
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

NCT05763082
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
roflumilast cream 0.3%, Zoryve, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 4:18 PM EDT
Completed No phase listed Observational

Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.

NCT04736433
View directory record Official record
Conditions
Heart Failure
Interventions
ACE inhibitor, Sacubitril/Valsartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6,066 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

NCT01206608
View directory record Official record
Conditions
Postoperative Pain
Interventions
SKY0402 + bupivacaine HCl, Mid-dose SKY0402 + bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

NCT07545226
View directory record Official record
Conditions
Healthy Participants
Interventions
Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Anaheim, California • South Miami, Florida • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 4:18 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

NCT06632990
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
BMS-984923, Midazolam, Caffeine, dextromethorphan
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

NCT02230696
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Baltimore, Maryland + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia

NCT02964325
View directory record Official record
Conditions
Hematologic Malignancies, Hypoproliferative Thrombocytopenia
Interventions
Mirasol platelets (MIR PLTs), Reference platelets (REF PLTs)
Device
Lead sponsor
Terumo BCTbio
Industry
Eligibility
Not listed
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

NCT00846885
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan Succinate, Imitrex®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

NCT02584257
View directory record Official record
Conditions
Mild Persistent Asthma
Interventions
methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI
Other · Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
17
States / cities
Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

NCT02005666
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656
View directory record Official record
Conditions
Multi-drug Resistant Tuberculosis
Interventions
Pretomanid
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 19, 2026, 4:18 PM EDT
Completed No phase listed Observational

Room Air Levels of Harmful and Potentially Harmful Constituents After Heated Tobacco Product Use and Cigarettes

NCT06476405
View directory record Official record
Conditions
Tobacco Smoking, Tobacco Use
Interventions
Not listed
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Azithromycin 600 Mg Tablets, Fasting

NCT00834756
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

NCT00840216
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 19, 2026, 4:18 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotine Pouch Pharmacokinetics Abuse Liability

NCT07476144
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.
Drug
Lead sponsor
JT International SA
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 19, 2026, 4:18 PM EDT